Fixed ratio combination of basal insulin and GLP-1 receptor agonist
Insulin icodec and semaglutide (IcoSema) subcutaneous once weekly titrated
ICOSEMA_SC_TIT_QW
Titrated by the trial algorithm up to the labeled maximum.
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.83 (-1.29 to -0.34) | 0.90 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.93 (-1.67 to -0.14) | 0.77 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 0.78 (-1.77 to 3.79) | 0.23 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Semaglutide 1.0 mg subcutaneous once weekly | MD 4.49 (-0.53 to 9.13) | 0.09 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.32 (0.00 to 20.49) | 0.52 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.92 (0.19 to 4.01) | 0.51 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.75 (0.97 to 3.23) | 0.24 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.10 (0.68 to 6.57) | 0.41 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.46 (1.83 to 6.72) | 0.39 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.41 (1.07 to 5.20) | 0.53 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.72 (0.99 to 3.03) | 0.47 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.29 (0.54 to 2.99) | 0.58 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 4.76 (0.71 to 32.30) | 0.28 |
Trials
- COMBINE 2A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Semaglutide, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With a GLP 1 Receptor Agonist. COMBINE 22022 · 683 randomized · 52 weeks
- COMBINE 1A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Insulin Icodec, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin.2022 · 1,291 randomized · 52 weeks